Service is in preparation Official β release coming soon. Some features are still being adjusted.

Investical Earnings & investing calendar Earnings & investing calendar
/
PPacific Biosciences of California, Inc. logo
PACBNASDAQ

Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc.
Loading price data…
Loading price data…
Chart type
Interval
Moving averages
Up/down colors

Share screenshot

Recent & upcoming events

Aug 7
Filing Time TBD
Quarterly report (10-Q) filing due (est.)
Add to Google Calendar
Aug 5
Earnings 16:30
Q2 earnings
Add to Google Calendar
Earnings 16:30
Earnings call (第2四半期)
Add to Google Calendar
May 7
Earnings Time TBD
Q1 earnings
Add to Google Calendar
Feb 12
Earnings Time TBD
Full-year earnings
Add to Google Calendar
2025
Nov 5
Earnings Time TBD
Q3 earnings
Add to Google Calendar
Aug 7
Earnings Time TBD
Q2 earnings
Add to Google Calendar
May 8
Earnings Time TBD
Q1 earnings
Add to Google Calendar
Feb 13
Earnings Time TBD
Full-year earnings
Add to Google Calendar
Jan 28
Est.
Earnings 16:05 approx.
FY earnings (predicted)
Add to Google Calendar
Mar 1
Est.
Filing Time TBD
Annual report (10-K) filing due (est.)
Add to Google Calendar
Jun 4
Est.
Shareholder meeting Time TBD
Annual meeting (est.)
Add to Google Calendar

KPI highlights

FY25
Revenue $160M YoY +3.9%
Operating income $-554M margin -346.2%
Net income $-546M YoY —
EPS $-1.82 YoY —
P/E —
ROE -10214.5% Equity ratio 1% Typical equity ratios vary a lot by industry. Banks, brokerages, and other financial companies tend to run lower ratios because leverage (using other people's capital) is core to their business model — a low ratio there isn't a sign of financial weakness.

Company news

Ownership over time

Share of total shares outstanding (disclosed major holdings + undisclosed)（2013–2026）

機関投資家 12.8%未開示 87.2%20132015201720192021202320252026
機関投資家 12.8%未開示 87.2%13Q214Q315Q417Q118Q219Q320Q422Q123Q224Q326Q1
機関投資家未開示・浮動株

「国内機関」は信託銀行の名義口座（年金・パッシブ・一部海外資本を含む）を集計し、実質保有者へは分解していません。分類は開示名称からの推定です。

Top shareholders — rank & share

ARK Investment Man 12%ARK Investment Management LLCBirchview Capital, 0.5%Birchview Capital, LP20132015201720192021202320252026
ARK Investment Man 12%ARK Investment Management LLCBirchview Capital, 0.5%Birchview Capital, LP13Q214Q315Q417Q118Q219Q320Q422Q123Q224Q326Q1

Top shareholders — actual figures (as of 2026)

Holder Shares held Ratio Source
ARK Investment Management LLC 36,273,288 12.0% 13F
Birchview Capital, LP 1,500,000 0.5% 13F
Russell Investments Group, Ltd. 467,288 0.2% 13F
MetLife Investment Management, LLC 127,090 0.0% 13F
BNP PARIBAS FINANCIAL MARKETS 65,398 0.0% 13F
Wealth Architects, LLC 48,725 0.0% 13F
NEUBERGER BERMAN GROUP LLC 30,941 0.0% 13F
Jump Financial, LLC 25,492 0.0% 13F
SBI Securities Co., Ltd. 20,984 0.0% 13F
NISA INVESTMENT ADVISORS, LLC 3,642 0.0% 13F

Source：SEC EDGAR（DEF 14A・13D/G・13F）　Classification inferred from disclosed names

F-Score (Piotroski)

3/9

Checks financial health against 9 criteria and shows how many are met as a fraction (more ✓ marks is healthier). Items with no data are shown as “—” — they're simply excluded from judgment, not counted against the score.

✗ Positive ROA ROA -69.7%
✗ Positive operating cash flow $-111M
✗ ROA improved YoY -24.6% → -69.7%
✓ Operating CF exceeds net income (accrual quality) OCF $-111M / net income $-546M
✗ Equity ratio improved* Substitute for the original “decrease in long-term debt” 40.2% → 0.7%
✗ Current ratio improved 7.48× → 5.15×
✗ No dilution (shares outstanding did not increase) 294,418,000 → 301,956,000
✓ Gross margin improved 24.2% → 28.6%
✓ Asset turnover improved 0.12× → 0.20×

This score is reference information based on our own financial metrics. It is NOT a credit rating issued by a credit rating agency under Article 66-27 of the Financial Instruments and Exchange Act, and is NOT investment advice or a recommendation. Make investment decisions at your own responsibility.

Fact checklist

FY25
Equity ratio 0.7%
Current ratio 5.1×
Years of positive operating CF 1 of last 12 yrs
Payout ratio 0%
Latest fiscal year result Loss (net loss $546M)

Performance history

Last 10 years
$0M$50M$100M$150M$201M FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

Income & assets

Unit: $1M
Item FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Revenue 90.793.578.6—78.9131128201154160
Operating income -71.2-89.8-101-101-104-210-307-334-474-554
Ordinary income ——————————
Net income -74.4-92.2-103-84.129.4-181-314-307-310-546
Total assets 1381441701484142,0071,7671,7461,260784
Equity 84.786.111454.93357915637015075.35

A “—” means data wasn't available for that period — it's not a display error or an unusual value.

Indicators & cash flow

Unit: $1M
Item FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
EPS ——$-0.76$-0.55$0.18$-0.89$-1.40$-1.21$-1.13$-1.82
ROE -87.8%-107.1%-89.9%-153.2%8.8%-22.9%-55.8%-43.7%-61.2%-10214.5%
Operating CF -67.9-67.5-66.4-78.319.5-111-263-259-206-111
Investing CF -14.9-1.55-38.462.0-219-6791164.60124115
Financing CF 65.968.810726.52521,1709.62109-43.03.43
FCF ————18.5-117-280-268-212-119

A “—” means data wasn't available for that period — it's not a display error or an unusual value.

Source: SEC EDGAR (10-K, etc.) (fetched 2026-07-03) *Some metrics supplemented from additional sources

Sector positioning

Relative standing within the sector
Is this information incorrect?

Data provided by Twelve Data